Iterum Anxiously Awaiting Other Results After SURE 3 Failure

 
• By Leah Samuel

Iterum’s antibiotic sulopenem missed its endpoint by the equivalent of one patient. The company believes the Phase III data could still support its NDA for urinary tract infections.

Illustration of bacteria on colorful background, model of bacteria, microbes, microorganisms,
Sulopenem has shown broad-spectrum activity against most Gram-positive and Gram-negative bacteria

More from Immunological

More from Therapy Areas